According to Futu News on March 30, $DIAGENS-B (02526.HK)$ the stock opened high on its first day, surging by 121.21%. As of the time of writing, it was trading at HKD 219 per share. With each lot consisting of 50 shares, excluding handling fees, investors earned HKD 6,000 per lot.
Source of market information: Futu Securities
According to previous reports, in the grey market trading session conducted by Futu on the previous trading day, Deshi-B closed with a gain of 101.52%, trading at HKD 199.5 per share. Each lot consists of 50 shares, and excluding handling fees, investors earned HKD 5,025 per lot.
In addition, according to previously disclosed information, during the public offering phase, Deshi-B received subscriptions 1,073.37 times the number of shares offered. The final number of shares allocated for public offering was 799,950 shares, accounting for approximately 10% of the total number of shares available for subscription. A total of approximately 115,017 valid applications were received, with around 14,278 applications processed. The percentage of successfully allotted shares relative to the total applied-for shares in a one-lot application was approximately 3%.
Furthermore, during the international placement phase, Deshi-B received subscriptions 3.45 times the number of shares offered. The final number of international placement shares was 71,992,500 shares, representing 90% of the total shares available for subscription.
Company Overview
De Shi is a medical device company focused on the development of medical imaging products and services. It has developed a diversified portfolio, including six medical imaging software products (one core product in the registration stage, AI AutoVision®, one commercialized product, AutoVision®, and four other medical imaging software candidates in the preclinical stage), three commercialized medical devices, four major reagents and consumables, and two technology-licensed products.
According to Frost & Sullivan, the company ranks first in China's chromosome karyotyping analysis sector based on sales revenue for 2024, with a market share of 30.6%. Its leading position is built on an outstanding track record in technological research and commercialization, including the success of its proprietary computer-aided chromosome analysis software, AutoVision®.
The core competitive advantage of its flagship product AI AutoVision® lies in the company’s self-developed iMedImage® medical imaging foundational model. As of the latest practicable date, it effectively supports 19 types of medical imaging modalities (such as chromosomes, CT, MRI, ultrasound, and pathology), covering more than 90% of clinical medical imaging scenarios, including reproductive health, hematologic malignancies, and other clinical applications.
Financial Overview
De Shi's revenue increased by 33.1% from RMB 52.8 million in 2023 to RMB 70.4 million in 2024, primarily due to income generated from technology licensing in 2024. For 2023 and 2024, as well as the nine months ended September 30, 2024, and September 30, 2025, the company’s gross profits were RMB 37.5 million, RMB 46.1 million, RMB 8.4 million, and RMB 84.7 million, respectively; during the same periods, the gross profit margins were 71.0%, 65.5%, 42.9%, and 75.9%, respectively.
Don't miss out on the IPO surge! The trailing stop order feature can help you lock in profits automatically.
The core functionality lies in 'moving the stop-loss based on market prices.' Simply put: when the stock price rises, your stop-loss line rises accordingly; when the stock price falls, the stop-loss line remains unchanged, and if it drops below the percentage you set, the system will automatically sell for you!
Editor/Joe